Skip to main content
Premium Trial:

Request an Annual Quote

Dyadic Raises $3M from Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyadic International today announced it has raised $3 million from a completed private placement with two unnamed investors.

The proceeds will be used for working capital, including for R&D, and general corporate purposes, the Jupiter, Fla., company said in a statement.

The notes, which will pay interest quarterly at a rate of 8 percent annually, are convertible at the holder's option after Jan. 1, 2011 into shares of Dyadic's common stock. The conversion price is $1.82, 120 percent of the company's average share price for the 30 days prior to the closing date. The notes mature on Jan. 1, 2013.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.